 Connection
John Curtin to Ovarian Neoplasms
This is a "connection" page, showing publications John Curtin has written about Ovarian Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.283 |
|
|
|
-
Chern JY, Curtin JP. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. Curr Treat Options Oncol. 2016 Jan; 17(1):1.
Score: 0.372
-
Muggia F, Cannon T, Safra T, Curtin J. Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer. J Natl Cancer Inst. 2011 Jan 19; 103(2):160-1.
Score: 0.262
-
Boyd LR, Novetsky AP, Curtin JP. Ovarian cancer care for the underserved: are surgical patterns of care different in a public hospital setting? Cancer. 2011 Feb 15; 117(4):777-83.
Score: 0.259
-
Blank SV, Curtin JP. More than a name. J Clin Oncol. 2007 Aug 10; 25(23):3551; author reply 3557-8.
Score: 0.208
-
Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol. 2003 Jun; 30(3):401-12.
Score: 0.156
-
Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV. Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression. Gynecol Oncol. 2020 04; 157(1):280-286.
Score: 0.124
-
Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2017 Feb; 144(2):279-284.
Score: 0.099
-
Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 07; 15(7):1557-67.
Score: 0.096
-
Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer. 2013 Nov; 23(9):1577-82.
Score: 0.080
-
Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Ann Surg Oncol. 2014 May; 21(5):1468-73.
Score: 0.080
-
Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist. 2012; 17(12):1534-40.
Score: 0.072
-
Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, Donach ME, Curtin J, Novetsky A, Grenader T, Lai WC, Gabizon A, Boyd L, Muggia F. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011 Oct; 10(10):2000-7.
Score: 0.069
-
Andreopoulou E, Chen T, Liebes L, Curtin J, Blank S, Wallach R, Hochster H, Muggia F. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer Chemother Pharmacol. 2011 Aug; 68(2):457-63.
Score: 0.065
-
Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 2010 Dec; 119(3):451-6.
Score: 0.064
-
Safra T, Andreopoulou E, Levinson B, Borgato L, Pothuri B, Blank S, Tiersten A, Boyd L, Curtin J, Muggia F. Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. Anticancer Res. 2010 Sep; 30(9):3243-7.
Score: 0.064
-
Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, Jacobs A, Curtin J, Muggia F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol. 2007 Apr; 18(4):716-21.
Score: 0.050
-
Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, Lee S, Sorich J, Dellenbaugh C, Muggia FM. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5912-9.
Score: 0.045
-
Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Aug; 94(2):368-74.
Score: 0.042
-
Lu MJ, Sorich J, Hazarika M, Kim M, Del Priore G, Jacobs AJ, Chiang C, Liu PC, Fusco E, Curtin JP, Muggia FM. Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. Hematol Oncol Clin North Am. 2003 Aug; 17(4):969-75.
Score: 0.039
-
Harlap S, Olson SH, Curtin JP, Caputo TA, Nakraseive C, Sanchez D, Xue X. Epithelial ovarian carcinoma and fertility of parents. Epidemiology. 2002 Jan; 13(1):59-65.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|